Abingdon Health signs contract to manufacture lateral flow device components

Francesca Morgan
Vox Newswire
11:16, 17th May 2022

Abingdon Health (ABDX Follow | ABDX) said it has signed a significant contract with a European customer for the manufacture of lateral flow device (LFD) components for a COVID-19 antigen test.

The contract, which is for an initial period of 12 months with an option to extend, will start with the primary production of the key biochemical-sprayed nitrocellulose component of the LFD.

There is also an option to expand to other aspects of device manufacture including production and lamination of other membrane components and production of complete foiled devices.

Abingdon, which develops and manufactures rapid tests, said the contract is with a European customer with the initial phase worth a minimum of £2.7m (based on minimum specified monthly order quantities and pricing at current GBP/USD exchange rates) for the first year.

Stock Chart | ABDX

While all raw materials required for production will be provided by the customer, there will be an initial technical transfer process which is anticipated to take approximately two months.

Commenting on the announcement this morning, Chris Yates, CEO of Abingdon Health, told investors: “We are pleased to have signed this contract with our European partner.”

The contract highlights the strengths of Abingdon’s flexibility in being able to offer a range of first-class contract services across primary and secondary production. We continue to make commercial progress in other areas and look forward to updating the market in due course.”

Abingdon Health, a Yorkshire-based company that was founded in 2008, said it continues to make commercial progress in other areas, adding that it will update the market in due course.

Follow News & Updates from Abingdon Health here: Follow | ABDX

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist